<p>随着全球市场应对中东紧张局势和能源市场波动的复杂性，美国主要股票指数表现出韧性，纳斯达克综合指数在混合的劳动数据和谨慎的地缘政治缓和背景下领先上涨。在这种环境中，识别高增长科技股需要寻找那些能够对经济条件变化表现出强大适应能力，并具备即使在更广泛市场不确定性中也能蓬勃发展的创新能力的公司。</p>
<h3>全球十大高增长科技公司</h3>
<table>
<thead>
<tr>
<th>名称</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>增长评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hacksaw</td>
<td>24.17%</td>
<td>25.33%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Giant Network Group</td>
<td>36.46%</td>
<td>42.98%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shengyi TechnologyLtd</td>
<td>24.24%</td>
<td>32.49%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>苏州 TFC 光通信</td>
<td>43.76%</td>
<td>38.73%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>中基光电</td>
<td>35.32%</td>
<td>37.30%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shengyi Electronics</td>
<td>26.92%</td>
<td>36.01%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Unimicron Technology</td>
<td>21.22%</td>
<td>69.47%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Co-Tech Development</td>
<td>34.37%</td>
<td>65.79%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>苏州东山精密制造</td>
<td>36.66%</td>
<td>84.97%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen Therapeutics Holdings</td>
<td>64.21%</td>
<td>83.56%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们全球高增长科技和人工智能股票筛选器中的 199 只股票的完整列表。</p>
<p>我们将从筛选结果中选取一些进行分析。</p>
<h2>Pharming Group (ENXTAM:PHARM)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Pharming Group N.V. 是一家生物制药公司，专注于开发和商业化用于罕见疾病的蛋白质替代疗法和精准医疗，业务覆盖美国、欧洲及其他国际市场，市值为 10.1 亿欧元。</p>
<p><strong>运营：</strong> Pharming Group 的收入主要来自其产品 Ruconest® 和 Joenja®，其中 Ruconest® 贡献了 3.1792 亿美元，Joenja® 贡献了 5821 万美元。该公司专注于罕见疾病的治疗，服务于美国、欧洲及国际市场。</p>
<p>Pharming Group 在生物技术领域的最新进展凸显了其在高增长科技行业的潜力，特别是在 CHMP 对 Joenja® 治疗 APDS 的积极意见之后，为关键的 EC 决策奠定了基础。这一进展与其财务回升相辅相成，预计 2025 年收入将从 2024 年的 2.97 亿美元跃升至 3.76 亿美元，净利润将从之前的亏损转为 285 万美元。研发工作依然强劲，这对维持创新和在罕见疾病治疗市场的竞争力至关重要。这些因素共同突显了 Pharming 在将科学进步转化为商业可行解决方案方面的轨迹，增强了其在专业医疗市场的影响力。</p>
<ul>
<li>解锁我们对 Pharming Group 股票分析的全面见解，请查看此健康报告。</li>
<li>通过我们的历史报告获取 Pharming Group 过去趋势和表现的见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0b975b67-eb09-4f0d-a0c0-7a08bd4f1141/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0b975b67-eb09-4f0d-a0c0-7a08bd4f1141/chart/revenue-and-expenses-breakdown"/></p>
<p>截至 2026 年 4 月的 ENXTAM:PHARM 收入和支出明细</p>
<h2>Ruijie Networks (SZSE:301165)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> Ruijie Networks Co., Ltd. 从事网络设备、网络安全产品和云桌面解决方案的设计、研发和销售，业务覆盖中国及国际市场，市值为 641.4 亿人民币。</p>
<p><strong>运营：</strong> Ruijie Networks 的收入主要来自网络设备，贡献了 125.2 亿人民币，其次是云桌面解决方案和网络安全产品，分别贡献了 57.288 亿人民币和 49.372 亿人民币。</p>
<p>Ruijie Networks 展现出强劲的财务增长，过去一年收入从 117 亿人民币增长至 143 亿人民币，净收入从 5.74 亿人民币上升至 6.96 亿人民币。这一表现得益于 36.7% 的显著年盈利增长率，超过了通信行业平均水平 10% 以上。公司对创新的承诺在其战略研发投资中得以体现，这对在快速发展的科技领域保持竞争优势至关重要。预计未来三年，Ruijie Networks 的盈利将以约 36% 的年增长率增长，良好的市场机会将进一步推动其技术产品的扩展。</p>
<ul>
<li>在此深入了解 Ruijie Networks 的完整分析健康报告。</li>
<li>通过我们的详细历史表现报告评估 Ruijie Networks 的过去表现。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a0c69abc-cd2d-4e42-9326-ee1a888b1f87/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a0c69abc-cd2d-4e42-9326-ee1a888b1f87/chart/earnings-and-revenue-growth"/></p>
<p>截至 2026 年 4 月的 SZSE:301165 盈利和收入增长</p>
<h2>Dexerials (TSE:4980)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Dexerials Corporation，市值为 3625.3 亿日元，专注于电子元件、粘合材料和光学材料的生产和销售，主要在日本市场。</p>
<p><strong>运营：</strong> 该公司通过其光学材料和组件部门产生收入，贡献了 466.2 亿日元，电子材料和组件部门则带来了 647.3 亿日元。</p>
<p>在充满挑战的环境中，Dexerials Corporation 设法保持了 8.9% 的稳定收入增长。考虑到过去九个月净收入从 233.6 亿日元下降至 212.7 亿日元，这一表现尤为显著，反映出强大的运营韧性。公司的创新承诺在其研发支出中得以体现，这仍然是其战略的关键方面，旨在促进技术进步并在持续演变的科技领域保持竞争力。</p>
<ul>
<li>在我们的健康报告中更深入地了解 Dexerials 的潜力。</li>
<li>查看 Dexerials 的过去业绩报告，以了解其过去的表现。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/95dbf7fd-a146-474e-9a1b-14bf2984e6ca/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/95dbf7fd-a146-474e-9a1b-14bf2984e6ca/chart/earnings-and-revenue-growth"/></p>
<p>TSE:4980 截至 2026 年 4 月的收益和收入增长</p>
<h2>总结</h2>
<ul>
<li>点击这里访问我们完整的 199 家全球高增长科技和人工智能股票索引。</li>
<li>已经拥有这些公司？将您的投资组合链接到 Simply Wall St，并获取有关您股票的新警告信号的提醒。</li>
<li>通过使用 Simply Wall St 加入聪明投资者的社区。它是免费的，并提供全球市场的专家级分析。</li>
</ul>
<h2>寻找新视角？</h2>
<ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>用显示强劲增长潜力的公司来充实您的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
<p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们基于历史数据和分析师预测提供评论，仅使用无偏见的方法，我们的文章不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
<h3><strong>新功能：</strong> 在一个地方管理您的所有股票投资组合</h3>
<p>我们为股票投资者创建了 <strong>终极投资组合伴侣</strong>，<strong>而且是免费的。</strong></p>
<p>• 连接无限数量的投资组合，并以一种货币查看您的总额</p>
<p>• 通过电子邮件或手机接收新警告信号或风险的提醒</p>
<p>• 跟踪您股票的公允价值</p>
<p>免费试用演示投资组合</p>

核心标普美国增长 ETF - iShares

全球科技股指数 ETF - iShares

全美成长股指数 MSCI ETF - Vanguard

<p>随着全球市场面临中东紧张局势和能源波动，美国股指，特别是纳斯达克综合指数，展现出韧性。高增长科技股备受关注，包括 Pharming Group、锐捷网络和 Dexerials，这些公司均表现出强劲的收入和盈利增长。Pharming 专注于罕见疾病治疗，锐捷在网络解决方案方面表现出色，而 Dexerials 则专注于电子元件。在市场不确定性中，这些公司在各自领域展现出适应性和创新能力，为未来增长奠定了良好基础</p>

<p>As global markets navigate the complexities of Middle East tensions and energy market volatility, major U.S. stock indexes have shown resilience, with the Nasdaq Composite leading gains amidst a backdrop of mixed labor data and tentative geopolitical de-escalation. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate robust adaptability to shifting economic conditions and possess innovative capabilities that can thrive even amid broader market uncertainties.</p>
<div class="lb-trans"><p>随着全球市场应对中东紧张局势和能源市场波动的复杂性，美国主要股票指数表现出韧性，纳斯达克综合指数在混合的劳动数据和谨慎的地缘政治缓和背景下领先上涨。在这种环境中，识别高增长科技股需要寻找那些能够对经济条件变化表现出强大适应能力，并具备即使在更广泛市场不确定性中也能蓬勃发展的创新能力的公司。</p>
</div><h3>Top 10 High Growth Tech Companies Globally</h3>
<div class="lb-trans"><h3>全球十大高增长科技公司</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Growth Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hacksaw</td>
<td>24.17%</td>
<td>25.33%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Giant Network Group</td>
<td>36.46%</td>
<td>42.98%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shengyi TechnologyLtd</td>
<td>24.24%</td>
<td>32.49%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Suzhou TFC Optical Communication</td>
<td>43.76%</td>
<td>38.73%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Zhongji Innolight</td>
<td>35.32%</td>
<td>37.30%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shengyi Electronics</td>
<td>26.92%</td>
<td>36.01%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Unimicron Technology</td>
<td>21.22%</td>
<td>69.47%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Co-Tech Development</td>
<td>34.37%</td>
<td>65.79%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Suzhou Dongshan Precision Manufacturing</td>
<td>36.66%</td>
<td>84.97%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen Therapeutics Holdings</td>
<td>64.21%</td>
<td>83.56%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名称</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>增长评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hacksaw</td>
<td>24.17%</td>
<td>25.33%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Giant Network Group</td>
<td>36.46%</td>
<td>42.98%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shengyi TechnologyLtd</td>
<td>24.24%</td>
<td>32.49%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>苏州 TFC 光通信</td>
<td>43.76%</td>
<td>38.73%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>中基光电</td>
<td>35.32%</td>
<td>37.30%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shengyi Electronics</td>
<td>26.92%</td>
<td>36.01%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Unimicron Technology</td>
<td>21.22%</td>
<td>69.47%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Co-Tech Development</td>
<td>34.37%</td>
<td>65.79%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>苏州东山精密制造</td>
<td>36.66%</td>
<td>84.97%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen Therapeutics Holdings</td>
<td>64.21%</td>
<td>83.56%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 199 stocks from our Global High Growth Tech and AI Stocks screener.</p>
<div class="lb-trans"><p>点击这里查看我们全球高增长科技和人工智能股票筛选器中的 199 只股票的完整列表。</p>
</div><p>We'll examine a selection from our screener results.</p>
<div class="lb-trans"><p>我们将从筛选结果中选取一些进行分析。</p>
</div><h2>Pharming Group (ENXTAM:PHARM)</h2>
<div class="lb-trans"><h2>Pharming Group (ENXTAM:PHARM)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Pharming Group N.V. is a biopharmaceutical company focused on developing and commercializing protein replacement therapies and precision medicines for rare diseases across the United States, Europe, and other international markets, with a market cap of €1.01 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Pharming Group N.V. 是一家生物制药公司，专注于开发和商业化用于罕见疾病的蛋白质替代疗法和精准医疗，业务覆盖美国、欧洲及其他国际市场，市值为 10.1 亿欧元。</p>
</div><p><strong>Operations:</strong> Pharming Group generates revenue primarily from its products Ruconest® and Joenja®, with Ruconest® contributing $317.92 million and Joenja® $58.21 million. The company focuses on therapies for rare diseases, serving markets in the United States, Europe, and internationally.</p>
<div class="lb-trans"><p><strong>运营：</strong> Pharming Group 的收入主要来自其产品 Ruconest® 和 Joenja®，其中 Ruconest® 贡献了 3.1792 亿美元，Joenja® 贡献了 5821 万美元。该公司专注于罕见疾病的治疗，服务于美国、欧洲及国际市场。</p>
</div><p>Pharming Group's recent strides in biotechnology underscore its potential within the high-growth tech sector, particularly following CHMP's positive opinion on Joenja® for treating APDS, setting the stage for a pivotal EC decision. This development complements their financial upturn, with 2025 witnessing a revenue jump to $376 million from $297 million in 2024 and a swing to net profits of $2.85 million from a prior loss. R&amp;D efforts remain robust, critical for sustaining innovation and market competitiveness in rare disease treatments. These factors collectively highlight Pharming's trajectory towards leveraging scientific advancements into commercially viable solutions, enhancing its footprint in specialized healthcare markets.</p>
<div class="lb-trans"><p>Pharming Group 在生物技术领域的最新进展凸显了其在高增长科技行业的潜力，特别是在 CHMP 对 Joenja® 治疗 APDS 的积极意见之后，为关键的 EC 决策奠定了基础。这一进展与其财务回升相辅相成，预计 2025 年收入将从 2024 年的 2.97 亿美元跃升至 3.76 亿美元，净利润将从之前的亏损转为 285 万美元。研发工作依然强劲，这对维持创新和在罕见疾病治疗市场的竞争力至关重要。这些因素共同突显了 Pharming 在将科学进步转化为商业可行解决方案方面的轨迹，增强了其在专业医疗市场的影响力。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of Pharming Group stock in this health report.</li>
<li>Gain insights into Pharming Group's past trends and performance with our Past report.</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁我们对 Pharming Group 股票分析的全面见解，请查看此健康报告。</li>
<li>通过我们的历史报告获取 Pharming Group 过去趋势和表现的见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0b975b67-eb09-4f0d-a0c0-7a08bd4f1141/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/0b975b67-eb09-4f0d-a0c0-7a08bd4f1141/chart/revenue-and-expenses-breakdown"/></p>
<p>ENXTAM:PHARM Revenue and Expenses Breakdown as at Apr 2026</p>
<div class="lb-trans"><p>截至 2026 年 4 月的 ENXTAM:PHARM 收入和支出明细</p>
</div><h2>Ruijie Networks (SZSE:301165)</h2>
<div class="lb-trans"><h2>Ruijie Networks (SZSE:301165)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Ruijie Networks Co., Ltd. is involved in the design, research, and sale of network equipment, network security products, and cloud desktop solutions both in China and internationally, with a market capitalization of CN¥64.14 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Ruijie Networks Co., Ltd. 从事网络设备、网络安全产品和云桌面解决方案的设计、研发和销售，业务覆盖中国及国际市场，市值为 641.4 亿人民币。</p>
</div><p><strong>Operations:</strong> Ruijie Networks generates revenue primarily from network equipment, contributing CN¥12.52 billion, followed by cloud desktop solutions and cyber security products at CN¥572.88 million and CN¥493.72 million, respectively.</p>
<div class="lb-trans"><p><strong>运营：</strong> Ruijie Networks 的收入主要来自网络设备，贡献了 125.2 亿人民币，其次是云桌面解决方案和网络安全产品，分别贡献了 57.288 亿人民币和 49.372 亿人民币。</p>
</div><p>Ruijie Networks has demonstrated robust financial growth, with a notable increase in revenue from CNY 11.7 billion to CNY 14.3 billion and net income rising from CNY 574 million to CNY 696 million over the past year. This performance is underpinned by a significant annual earnings growth rate of 36.7%, outpacing the Communications industry's average by over 10%. The company's commitment to innovation is evident in its strategic R&amp;D investments, crucial for maintaining competitive advantage in the rapidly evolving tech landscape. With earnings projected to grow by an impressive annual rate of approximately 36% over the next three years, Ruijie Networks is well-positioned to capitalize on market opportunities and expand its technological offerings further.</p>
<div class="lb-trans"><p>Ruijie Networks 展现出强劲的财务增长，过去一年收入从 117 亿人民币增长至 143 亿人民币，净收入从 5.74 亿人民币上升至 6.96 亿人民币。这一表现得益于 36.7% 的显著年盈利增长率，超过了通信行业平均水平 10% 以上。公司对创新的承诺在其战略研发投资中得以体现，这对在快速发展的科技领域保持竞争优势至关重要。预计未来三年，Ruijie Networks 的盈利将以约 36% 的年增长率增长，良好的市场机会将进一步推动其技术产品的扩展。</p>
</div><ul>
<li>Delve into the full analysis health report here for a deeper understanding of Ruijie Networks.</li>
<li>Assess Ruijie Networks' past performance with our detailed historical performance reports.</li>
</ul>
<div class="lb-trans"><ul>
<li>在此深入了解 Ruijie Networks 的完整分析健康报告。</li>
<li>通过我们的详细历史表现报告评估 Ruijie Networks 的过去表现。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a0c69abc-cd2d-4e42-9326-ee1a888b1f87/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/a0c69abc-cd2d-4e42-9326-ee1a888b1f87/chart/earnings-and-revenue-growth"/></p>
<p>SZSE:301165 Earnings and Revenue Growth as at Apr 2026</p>
<div class="lb-trans"><p>截至 2026 年 4 月的 SZSE:301165 盈利和收入增长</p>
</div><h2>Dexerials (TSE:4980)</h2>
<div class="lb-trans"><h2>Dexerials (TSE:4980)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Dexerials Corporation, with a market cap of ¥362.53 billion, specializes in the production and sale of electronic components, bonding materials, and optics materials primarily in Japan.</p>
<div class="lb-trans"><p><strong>概述：</strong> Dexerials Corporation，市值为 3625.3 亿日元，专注于电子元件、粘合材料和光学材料的生产和销售，主要在日本市场。</p>
</div><p><strong>Operations:</strong> The company generates revenue through its Optical Materials and Components segment, which contributes ¥46.62 billion, and the Electronic Materials and Components segment, bringing in ¥64.73 billion.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司通过其光学材料和组件部门产生收入，贡献了 466.2 亿日元，电子材料和组件部门则带来了 647.3 亿日元。</p>
</div><p>Dexerials Corporation, amid a challenging landscape, has managed to maintain steady revenue growth at 8.9% annually. This performance is particularly noteworthy given the slight dip in net income from JPY 23.36 billion to JPY 21.27 billion over the last nine months of reporting, reflecting robust operational resilience. The firm's commitment to innovation is mirrored in its R&amp;D spending which remains a critical aspect of its strategy, aiming to foster advancements and maintain competitiveness in the tech sector where continuous evolution is paramount.</p>
<div class="lb-trans"><p>在充满挑战的环境中，Dexerials Corporation 设法保持了 8.9% 的稳定收入增长。考虑到过去九个月净收入从 233.6 亿日元下降至 212.7 亿日元，这一表现尤为显著，反映出强大的运营韧性。公司的创新承诺在其研发支出中得以体现，这仍然是其战略的关键方面，旨在促进技术进步并在持续演变的科技领域保持竞争力。</p>
</div><ul>
<li>Take a closer look at Dexerials' potential here in our health report.</li>
<li>Examine Dexerials' past performance report to understand how it has performed in the past.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我们的健康报告中更深入地了解 Dexerials 的潜力。</li>
<li>查看 Dexerials 的过去业绩报告，以了解其过去的表现。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/95dbf7fd-a146-474e-9a1b-14bf2984e6ca/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/95dbf7fd-a146-474e-9a1b-14bf2984e6ca/chart/earnings-and-revenue-growth"/></p>
<p>TSE:4980 Earnings and Revenue Growth as at Apr 2026</p>
<div class="lb-trans"><p>TSE:4980 截至 2026 年 4 月的收益和收入增长</p>
</div><h2>Summing It All Up</h2>
<div class="lb-trans"><h2>总结</h2>
</div><ul>
<li>Click here to access our complete index of 199 Global High Growth Tech and AI Stocks.</li>
<li>Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.</li>
<li>Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里访问我们完整的 199 家全球高增长科技和人工智能股票索引。</li>
<li>已经拥有这些公司？将您的投资组合链接到 Simply Wall St，并获取有关您股票的新警告信号的提醒。</li>
<li>通过使用 Simply Wall St 加入聪明投资者的社区。它是免费的，并提供全球市场的专家级分析。</li>
</ul>
</div><h2>Searching for a Fresh Perspective?</h2>
<div class="lb-trans"><h2>寻找新视角？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>用显示强劲增长潜力的公司来充实您的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们基于历史数据和分析师预测提供评论，仅使用无偏见的方法，我们的文章不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div><h3><strong>New:</strong> Manage All Your Stock Portfolios in One Place</h3>
<div class="lb-trans"><h3><strong>新功能：</strong> 在一个地方管理您的所有股票投资组合</h3>
</div><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p>
<div class="lb-trans"><p>我们为股票投资者创建了 <strong>终极投资组合伴侣</strong>，<strong>而且是免费的。</strong></p>
</div><p>• Connect an unlimited number of Portfolios and see your total in one currency</p>
<div class="lb-trans"><p>• 连接无限数量的投资组合，并以一种货币查看您的总额</p>
</div><p>• Be alerted to new Warning Signs or Risks via email or mobile</p>
<div class="lb-trans"><p>• 通过电子邮件或手机接收新警告信号或风险的提醒</p>
</div><p>• Track the Fair Value of your stocks</p>
<div class="lb-trans"><p>• 跟踪您股票的公允价值</p>
</div><p>Try a Demo Portfolio for Free</p>
<div class="lb-trans"><p>免费试用演示投资组合</p>
</div>

High Growth Tech Stocks To Watch In April 2026

- 美股主要指数在中东紧张局势和能源市场波动中展现韧性。  
- 高增长科技股需具备应对经济变动的能力和创新潜力。  
- 几家公司如 Pharming 和 Ruijie Networks 实现了显著的营收及盈利增长。

2026 年 4 月需要关注的高增长科技股票